Quince Therapeutics, Inc. Common Stock

Day range

$29.84 – $37.00

Open

$30.50

Prev close

$31.73

Volume

138.74K

Market cap

—

Shares out

—

P/E

—

P/S

—

P/B

0.30

P/FCF

—

ROE

-88.1%

ROA

-77.1%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 9, 2026

• Executive officer departureOct 9, 2026

  Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer of the Company.

• Charter amendmentOct 6, 2026

  At the Special Meeting, the Company's stockholders approved an amendment to the Company's Certificate of Incorporation (the "Amendment") to increase the number of authorized shares of common stock from 250,000,000 to 275,000,000. The Amendment was filed with the Secretary of State of the State of Delaware on October 6, 2026, and effective as of such date.

• Director departureOct 2, 2026

  On September 30, 2026, each of June Bray, David Lamond and Christopher Senner (collectively, the "Resigning Directors") tendered conditional resignations from the Board of Directors ... effective as of two business days following the conclusion of the Company's Special Meeting of Stockholders ... and contingent upon the approval by the Company's stockholders of the following three proposals.

• Executive compensation changeSep 14, 2026

  In connection with his departure, on September 8, 2026, the Company and Mr. Ryan entered into a Separation Agreement and General Release of Claims ... Pursuant to the Separation Agreement ... the Company will pay Mr. Ryan a lump-sum cash amount of $1,014,489.04, comprised of (i) eighteen (18) months of his current base salary, (ii) 150% of his target annual bonus for 2026, pro-rated to September 8, 2026, and (iii) eighteen (18) months' of the monthly premiums that would be due for continuation coverage under ... COBRA.

• Executive compensation changeAug 27, 2026

  In connection with the conclusion of his service as the Company's President, Mr. Ryan will be eligible for certain severance benefits under the terms of his Executive Change in Control and Severance Agreement, dated September 1, 2023.

Days to cover

2.7

Short interest

59.94K

Avg volume

22.46K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
  positiveGlobeNewswire Inc.· Oct 9, 2026
• Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
  positiveBenzinga· May 18, 2026
• The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
  Zacks Investment Research· Mar 8, 2024
• Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
  Zacks Investment Research· Mar 7, 2024
• SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying
  Benzinga· Dec 8, 2023